Diabetes Mellitus Clinical Trial
Official title:
Impact of Self-care Education Program "Active Patient" in Metabolic Control, Cardiovascular Risk and Quality of Life in Patients With Type 2 Diabetes in Primary Care in the Basque Country: Randomized Clinical Trial of 2 Years of Follow up
| Verified date | November 2017 |
| Source | Osakidetza |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Main objective:To evaluate the effectiveness of the "Diabetes Self-Management Programme"
(DSMP) on the metabolic control, cardiovascular risk reduction, quality of life and
self-efficacy in adult patients with type 2 diabetes, compared with current standard care of
patients with type 2 diabetes, in the context of Osakidetza's Primary Care network.
Secondary objectives:
- To evaluate the impact of the implementation of DSMP in the use of health services.
- To assess the impact of DSMP in the cost of treatment of the involved population.
- To evaluate the improvement in physical activity and diet patterns among the
participants.
- To describe the feasibility of implementing the DSMP in the Basque Country's primary
health care system Methodology: Randomized clinical trial in which patients diagnosed
with type 2 diabetes aged between 18 and 80 years pertaining to 4 primary regions of the
Basque country, who agree to participate in the study, will be randomly assigned to two
groups: the intervention group (the DSMP programme) and the control group. The
intervention will be performed by trained patients with type 2 diabetes and health
professionals and it will consist in 6 group sessions of two and a half hours each, on a
weekly basis with a overall duration of 6 weeks. The session content includes techniques
for dealing with problems, promotion of exercise, nutrition concepts, proper use of
medication, effective communication and basic knowledge about diabetes and its
complications. The sessions are supported with educational material. The main outcome is
the improvement of HbA1c (glycated hemoglobin) levels. Secondary outcomes are reduction
of cardiovascular risk, increase of quality of life and self-efficacy. The results will
be analyzed at 6, 12 and 24 months after the intervention.
Hypothesis: An educational intervention on patients with type 2 diabetes mellitus based on
the program DSMP conducted by previously trained lay persons and health professionals,
improve metabolic control as measured on a 0.5% decrease in Hb A1c (Clar, 2010),compared to
regular health education. On the other hand, it is expected to see improvements in the
quality of life for these patients. The intervention may reduce the weight and cardiovascular
risk due to changes in the physical activity and diet patterns, getting to a more appropriate
use of health services and medication. It is expected that changes in the variables occur 6
months after the intervention and remain over the time
| Status | Completed |
| Enrollment | 594 |
| Est. completion date | December 1, 2016 |
| Est. primary completion date | December 30, 2014 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility |
Inclusion Criteria: - Adults over 18 years from four primary regions of the Basque Country: Araba, Bidasoa, Ezkerraldea- Enkarterri, Ekialde, with type 2 diabetes who have agreed to participate in the "Active Patient". Exclusion Criteria: - Adults over 80 years or patients with mental disorder that distorts reality (schizophrenia, bipolar disorder, Alzheimer's disease, psychosis, dementia) or morbidity which can interfere with the course, like chronic patients at home. |
| Country | Name | City | State |
|---|---|---|---|
| Spain | Osakidetza | Gasteiz / Vitoria | Alava |
| Lead Sponsor | Collaborator |
|---|---|
| Osakidetza | Department of Health Basque Government, Fondo de Investigacion Sanitaria, Kronikgune-- Association Centre of International Excellence in Research on Chronicity |
Spain,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change in Glycated hemoglobin | The investigators are going to measure the diference between basal Glycated Hemoglobin and 6,12 and 24 months Glycated Hemoglobin. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in Cardiovascular risk | The investigators will use the Framingham-Regicor function | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in quality of life | The investigators will use the ADDQoL-19 | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in self efficacy | The investigators will use the Stanford Spanish diabetes self-efficacy survey | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in health services utilization | The investigators will measure the number of visits to the general practitioner and nurse, number of visits to the emergency department and number of hospitalizations | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Introduction or removal of hypoglycaemic drugs | The investigators will compare the number of hypoglycaemic drugs before and after intervention. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Introduction or removal of antiplatelet drugs | The investigators will compare the number of antiplatelet drugs before and after intervention. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Introduction or removal of antihypertensive drugs | The investigators will compare the number of antihypertensive drugs before and after intervention. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Introduction or removal of lipid drugs | The investigators will compare the number of lipid drugs before and after intervention. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in the percentage of patients with HbA1c less than 7% | The investigators will consider HbA1c less than 7% as good control | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in BMI | BMI (Body mass index) | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in blood pressure | Systolic and diastolic blood pressure (SBP and DBP) | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in percentage of patients with SBP <140 and DBP <80 | The investigators will measure the diference between basal percentage of patients with SBP <140 and DBP <80 and 6,12 and 24 months percentage of patients with SBP <140 and DBP <80. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in the value of total cholesterol | The investigators will measure the diference between basal total cholesterol and 6,12 and 24 months total cholesterol. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in the value of HDL-cholesterol | The investigators will measure the diference between basal HDL-cholesterol and 6,12 and 24 months HDL-cholesterol. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in physical activity | The investigators will use the 7 day Physical Activity Recall | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention | |
| Secondary | Change in the diet composition | The investigators will use the PREDIMED study survey. And we´ll study the percentage of people who declaring eat 5 or more daily pieces of fruit and vegetables. | Measurements will be carried out before intervention and 6, 12 and 24 months after intervention |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |